Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.34 |
| ▸ | SLC2A2 | P11168 | 1/20 | 0.34 |
| ▸ | SLC2A3 | P11169 | 1/20 | 0.34 |
| ▸ | PDE9A | O76083 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4355992 | 1.00 | GPR119 (0.47) | GPR119CNR2SCN9AEPHX2CYP3A4 | |
| SCHEMBL1128443 | 1.00 | GPR119 (0.47) | GPR119CNR2SCN9AEPHX2CYP3A4 | |
| SCHEMBL1128678 | 0.84 | GPR119 (0.49) | GPR119CNR2CYP3A4CYP2C19SLC2A1 | |
| SCHEMBL4359294 | 0.79 | GPR119 (0.43) | GPR119CNR2CYP3A4SLC2A1SLC2A2 | |
| SCHEMBL1128505 | 0.75 | GPR119 (0.52) | GPR119CYP3A4CYP2C19 | |
| SCHEMBL1128552 | 0.75 | GPR119 (0.52) | GPR119CYP3A4CYP2C19 | |
| SCHEMBL1128741 | 0.75 | GPR119 (0.45) | GPR119CNR2CYP3A4CYP2C19HCRTR1 | |
| SCHEMBL4355567 | 0.75 | GPR119 (0.52) | GPR119CYP3A4CYP2C19 | |
| SCHEMBL4350332 | 0.75 | GPR119 (0.45) | GPR119CNR2CYP3A4CYP2C19HCRTR1 | |
| SCHEMBL2075668 | 0.73 | ABL1 (0.47) | SLC2A1SLC2A2SLC2A3PDE9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188098-B2 | GPR119 receptor agonists | HOFFMANN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188098-B2 | GPR119 receptor agonists | HOFFMANN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188098-B2 | GPR119 receptor agonists | HOFFMANN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | disclosed |
| WO-2009141238-A1 | GPR119 RECEPTOR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-11-26 | — | — | WO | disclosed |
| US-20090286812-A1 | GPR119 Receptor Agonists | ERICKSON SHAWN DAVID | 2009-11-19 | — | — | US | disclosed |
| US-20090286812-A1 | GPR119 Receptor Agonists | ERICKSON SHAWN DAVID | 2009-11-19 | — | — | US | disclosed |
| US-20090286812-A1 | GPR119 Receptor Agonists | ERICKSON SHAWN DAVID | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286812-A1 | GPR119 Receptor Agonists | GPR119, GPR27, GPR139 | GPR119 1/4885CNR2 101/4885SCN9A 1052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.